Re: Ipilimumab and Nivolumab Followed by Chemoradiotherapy as Bladder-sparing Treatment in Muscle-invasive Bladder Cancer: A Phase 2 Trial.
OpenAlex 토픽 ·
Bladder and Urothelial Cancer Treatments
Urinary Bladder and Prostate Research
Tissue Engineering and Regenerative Medicine
APA
Wenlong Lu, Lin Yee Chen (2026). Re: Ipilimumab and Nivolumab Followed by Chemoradiotherapy as Bladder-sparing Treatment in Muscle-invasive Bladder Cancer: A Phase 2 Trial.. European urology. https://doi.org/10.1016/j.eururo.2026.04.002
MLA
Wenlong Lu, et al.. "Re: Ipilimumab and Nivolumab Followed by Chemoradiotherapy as Bladder-sparing Treatment in Muscle-invasive Bladder Cancer: A Phase 2 Trial.." European urology, 2026.
PMID
42031581
같은 제1저자의 인용 많은 논문 (5)
- Autonomous Soft Nanorobots for Active Targeting and Therapy of Triple-Negative Breast Cancer.
- Integrative transcriptomic and machine learning analysis identifies core immune genes and pathways driving graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
- Exosomes and their cargo proteins in diagnosis, process and treatment of gastric cancer.
- Arachidonic acid metabolism as a novel pathogenic factor in gastrointestinal cancers.
- Author Correction: PPIA dictates NRF2 stability to promote lung cancer progression.